Coverage
Filings
| Filing | Date |
|---|---|
| Block Listing Application | 30 Nov 2023 |
| Holding(s) in Company | 29 Nov 2023 |
| GSK announces positive DREAMM-7 headline results | 27 Nov 2023 |
| Director/PDMR Shareholding | 21 Nov 2023 |
| Block listing Interim Review | 15 Nov 2023 |
| GSK receives positive CHMP opinion for momelotinib | 13 Nov 2023 |
| Director/PDMR Shareholding | 13 Nov 2023 |
| 3rd Quarter Results | 1 Nov 2023 |
GSK said Monday it has appointed Chief Commercial Officer Luke Miels as its next chief executive, succeeding Dame Emma Walmsley.
GSK PLC announced plans to invest $30 billion in the United States over the next five years to boost its research, development, and manufacturing capabilities.
GSK said on Monday that the U.S. Food and Drug Administration has accepted for review its application to expand the use of its respiratory syncytial virus vaccine, Arexvy, to at-risk adults aged 18 to 49.
| 1 Nov 2023 |
| Jemperli trial meets overall survival endpoint | 30 Oct 2023 |
| NMPA approves Vocabria+Rekambys in China | 26 Oct 2023 |
| New data for Arexvy, GSK’s RSV vaccine | 25 Oct 2023 |